Trial Profile
Phase II Study of Cetuximab and Bevacizumab in Esophageal Carcinoma That Failed First Line Therapy
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 26 Nov 2014
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Cetuximab (Primary)
- Indications Oesophageal cancer
- Focus Therapeutic Use
- 07 Oct 2008 Actual start date changed from Mar 2008 to Oct 2008 as reported by CT.gov
- 07 Oct 2008 Status changed from recruiting to withdrawn prior to recruitment as reported by CT.gov
- 16 Apr 2008 New trial record.